Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT06071728
Other study ID # 202204445
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 10, 2022
Est. completion date January 31, 2024

Study information

Verified date February 2024
Source University of Iowa
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The glycocalyx serves as the interface between flowing blood and endothelial cells, the single cell layer that lines blood vessels, and is crucial for normal blood vessel function. Specifically, the glycocalyx protects endothelial cells from oxidative stress and inflammation and enables blood vessel dilation, which is largely dependent on the bioavailability of the vasodilatory molecule nitric oxide. Importantly, glycocalyx thickness decreases with age and is predictive of major adverse cardiovascular events in older adults free of cardiovascular disease. Therefore, interventions aimed at restoring glycocalyx thickness in older adults are desperately needed. Endocalyx Pro is a commercially available glycocalyx precursor supplement, manufactured by Microvascular Health Solutions, designed to 1) repair a damaged glycocalyx, 2) protect against damage to the glycocalyx, and 3) synthesize new glycocalyx components, and has been used to increase glycocalyx thickness in humans. However, no study has tested if glycocalyx thickness restores glycocalyx thickness in older adults and improves blood vessel function. Thus, the purpose of this investigation is to determine if 12-weeks of Endocalyx Pro supplementation alters glycocalyx thickness and blood vessel function in older adults. The investigators will use a camera placed under the tongue to determine glycocalyx thickness. The investigators will measure blood vessel function by measuring brachial artery dilation with ultrasound and arterial stiffness using pressure probes placed on the carotid and femoral artery.


Recruitment information / eligibility

Status Completed
Enrollment 24
Est. completion date January 31, 2024
Est. primary completion date December 31, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 60 Years to 85 Years
Eligibility Inclusion Criteria: - Age 60-85 years - Able to undergo cardiovascular testing procedures including fasting overnight and holding selected morning medication doses. - Ability to understand and willingness to sign a written informed consent document. - Ability to lie comfortably for up to 90 minutes - Women only: Post-menopausal Exclusion Criteria: - Current or history of CVD disease (heart attack, stroke, heart failure, cardiomyopathy or peripheral artery disease, heart angioplasty/stent or bypass surgery, valve replacement, carotid endarterectomy, heart transplant. - Medical history of stroke or other neurological disorder or systemic illness that could potentially affect cognition or brain function (outside of a diagnosis of MCI, Alzheimer's Disease) or could affect their safety or comfort while undergoing the imaging or cardiovascular studies. - Subjects with evidence of cardiovascular disease at baseline or during the exercise test (evidence of myocardial infarction, abnormal cardiac arrhythmia, myocardial ischemia, conduction delays, >1mm ST segment depression or elevation; >3 beat ventricular tachycardia; atrial fibrillation) will be excluded from the study. - Wilson's disease, hemochromatosis - Individuals taking clonidine or other short-acting beta blocker - Resting blood pressure > 149 mmHg systolic and/or 99mmHg diastolic - BMI > 40 kg/m2 - Medical history of chronic major psychiatric or current diagnosis of major psychiatric disease (other than dementia). - Unable to provide informed consent due to cognitive impairment - Current clinically abnormal thyroid function not adequately regulated by thyroid hormone supplementation or medication. - Allergic to olives, artichokes, grapes or melons - Current tobacco user or history of tobacco use within the past 3 months (cigarettes, cigars, chewing tobacco, hookah, electronic cigarettes) or living with someone who smokes/has smoked in the past 3 months. - Current diagnosis of diabetes (Type I or insulin dependent Type II) - Current diagnosis of COPD, cystic fibrosis, emphysema, chronic bronchitis - History of renal failure, dialysis or kidney transplant - Current diagnosis or history of liver disease or HIV/AIDS, or cancer requiring chemotherapy or radiation. - Current diagnosis or history of rheumatoid arthritis, systemic lupus erythematosus, Wegener's granuomatosis - Vulnerable populations (prisoners, etc) will not be eligible. - Unwillingness to wash out from a vitamin or dietary supplement regime prior to enrollment and maintain throughout the duration of the study. - Inability to comply with experimental instructions. - Uncontrolled intercurrent illness that would limit compliance with study requirements per investigator. - Inability to fast or hold morning medications doses until after testing is complete. - Hormone replacement use within the past 6 months - Currently enrolled in another study using an study medication, supplement, device or intervention. - Initiation of a new prescription medication or change in dose/frequency in the past three months. Individuals will be become eligible after the medication/dose/frequency has been stable for 3 months.

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Endocalyx Pro (Microvascular Health Solutions, US Patent Number: 9943572)
Subjects will receive Endocalyx Pro (Microvascular Health Solutions, US Patent Number: 9943572) (3,712mg) or placebo for 12 weeks.

Locations

Country Name City State
United States University of Iowa Iowa City Iowa

Sponsors (1)

Lead Sponsor Collaborator
University of Iowa

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Brachial artery flow-mediated dilation (FMD) Conduit artery vascular endothelial function Baseline and 12 weeks
Primary Perfused boundary region (PBR) Microvascular endothelial glycocalyx thickness Baseline and 12 weeks
See also
  Status Clinical Trial Phase
Completed NCT05433233 - Effects of Lifestyle Walking on Blood Pressure in Older Adults With Hypertension N/A
Recruiting NCT06032065 - Sequential Multiple Assessment Randomized Trial of Exercise for PAD: SMART Exercise for PAD (SMART PAD) Phase 3
Completed NCT05293730 - Trial of the Impact of the Electronic Frailty Integrated With Social Needs N/A
Recruiting NCT03932162 - Gene Expression Changes In Young and Geriatric Skin Early Phase 1
Completed NCT04064528 - Effects of Age on Amino Acid Delivery to Tendon N/A
Completed NCT03366129 - Blood-Brain Barrier Disruption in People With White Matter Hyperintensities Who Have Had a Stroke
Completed NCT06029920 - Influence of Overground Walking on Biomarkers, Cognitive Function, and Quality of Life in Elderly With Mild Cognitive Impairment N/A
Recruiting NCT05566938 - Study to Design a Precision Nutrition Strategy at a Group Level in the Elderly N/A
Recruiting NCT05543980 - Leg Heat Therapy in Elderly Individuals Phase 2
Completed NCT04894929 - Comprehensive Geriatric Assessment in the Monitoring of Functional Improvement N/A
Not yet recruiting NCT06071130 - Emotion, Aging, and Decision Making N/A
Enrolling by invitation NCT04641663 - Multi-target Dietary Supplement Tolerability in an Aging Population (MTDSST) N/A
Completed NCT04088006 - The Evaluation of Efficacy and Safety of Hyaluronic Acid Injection on Skin Moisturization and Elasticity N/A
Completed NCT03695081 - Patient Pathway Pharmacist - Optimal Drug-related Care N/A
Recruiting NCT05424263 - Acetate and Age-associated Arterial Dysfunction Phase 2
Completed NCT05601713 - Mitigating Heat-induced Physiological Strain and Discomfort in Older Adults Via Lower Limb Immersion and Neck Cooling N/A
Completed NCT04551339 - Zinc Versus Multivitamin Micronutrient Supplementation in the Setting of COVID-19 N/A
Recruiting NCT04997577 - Speech Perception and High Cognitive Demand N/A
Completed NCT05922475 - Efficacy of Pre-sleep or Post-exercise Protein During 12 Weeks of Resistance Exercise Training N/A
Completed NCT04015479 - Peanut Protein Supplementation to Augment Muscle Growth and Improve Markers of Muscle Quality and Health in Older Adults N/A